摘要
目的:寻找丙戊酸药物浓度与CYP2C19基因多态性的关系,以便临床根据患者的基因型进行个体化给药。方法:运用血药浓度监测仪测定患者血药浓度和变性高效液相色谱法检测癫痫患者的CYP2C19基因多态性位点,对二者结果进行相关性分析。结果:51名汉族癫痫患者中有29名携带突变型CYP2C19基因,其中19名(65.52％)患者丙戊酸实际血药浓度较预期的血药浓度升高,血药浓度分布曲线右移。结论:CYP2C19参与丙戊酸的代谢。对于含突变型CYP2C19基因的患者应给予小剂量丙戊酸,以减少药物不良反应的发生和药物资源的浪费。
OBJECTIVE To investigate the association between valproic acid (VAP) plasma concentration at steady state (Css) and CYP2C19 gene polymorphisms for better individualized medication. METHODS The VPA Css of patients with epilepsy was measured, and the CPY2C19 genotype was determined by denatured HPLC. RESULTS Among the 51 cases tested, 29 carry at least one of the mutant CYP2C19 * 2 or CYP2C19 * 3 allele. Nineteen cases with the mutant CYP2C19 alleles had a higher VPA Css as compared to the predicted value and a better control of clinical symptoms. CONCLUSIONS Our data suggest that VPA is metabolized by CYP2C19. VPA should be administrated carefully to those patients with a mutant CYP2C19 allele to prevent adverse effects.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2003年第11期670-673,共4页
Chinese Journal of Hospital Pharmacy
